Company profile
Freeline changing lives by innovative gene therapies
A leading biotechnology company focused on innovative liver directed gene therapies for bleeding disorders and other debilitating, chronic diseases
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
CH01 | Transaction MzUzMDM1NTg1M2FkaXF6a2N4
Published 03 Jul 2026 16:17
CH01 | Transaction MzUzMDM1NTc1OWFkaXF6a2N4
Published 03 Jul 2026 16:15
CH01 | Transaction MzUzMDM1NTY5NWFkaXF6a2N4
Published 03 Jul 2026 16:14
CS01 | Transaction MzUxMjc2MzQyMGFkaXF6a2N4
Published 28 Mar 2026 13:03
PSC07 | Transaction MzUxMjc2MTM2M2FkaXF6a2N4
Published 26 Mar 2026 12:14
PSC02 | Transaction MzUxMjc2MTI2NWFkaXF6a2N4
Published 26 Mar 2026 12:13
Last confirmation statement made up date
Last accounts made up date
CERTNM | Transaction MzQzNzU1MTI3NWFkaXF6a2N4
Published 27 Sep 2024 03:23
MR04 | Transaction MzQzMzQ5NzIzOGFkaXF6a2N4
Published 27 Aug 2024 17:14
MR04 | Transaction MzQzMzEzMjQ5NGFkaXF6a2N4
Published 22 Aug 2024 17:41
MR04 | Transaction MzQzMzEzMjQ4NGFkaXF6a2N4
Published 22 Aug 2024 17:40
Company registered at Companies House
1 Feb 2020 to 31 Aug 2023
To introduce advanced computational techniques and develop a new platform to accelerate discovery of novel and effective gene therapies to treat currently incurable diseases. To deliver new treatments faster and in a cost-effective manner.
1 Feb 2019 to 31 Mar 2022
Freeline is requesting a change of scope to project number 104902 – “Using AAV gene therapy to treat rare kidney disease” that would redistribute funds to enable critical safety risk mitigation experiments to be performed within the timelines of the grant.
1 Nov 2018 to 31 Oct 2021
"The rapid development of novel treatments called Advanced Therapies, such as cell therapies and gene therapies have required new manufacturing facilities and technologies worldwide. Manufacturing of gene therapy viral vectors for human use requires specialised high-quality manufacturing facilities and there is currently insufficient such capacity in the ...
1 Nov 2018 to 31 Jan 2021
"The rapid development of Gene Therapy Medicinal Products (GTMPs) requires new manufacturing processes and facilities. Gyroscope Therapeutics Ltd and Freeline Therapeutics Ltd are UK-based SMEs developing gene therapies for different indications but which are both delivered via adeno-associated viral (AAV) vectors. Gyroscope and Freeline intend to co-deve...
1 Dec 2017 to 31 Jan 2020
The rapid development of novel treatments called Advanced Therapies, such as gene therapies that provide the correct proteins, have required new, manufacturing facilities worldwide. Freeline Therapeutics Limited (Freeline), a UK company that makes gene therapies to treat bleeding and metabolic disorders, will work with the Cell and Gene Therapy Catapult (...
